Axial Biotech Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Axial Biotech Inc.
With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.
GSK sold to Aspen Global a group of products in Australia for $270 million. PE firm Cinven paid $730 million for branded and generics company Mercury Pharma. Debt offerings overwhelmingly were the most popular method of financing in both biopharma and device industries.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing